SpyGlass Pharma (SGP) awards 27,400 stock options to director Habib J. Dable

Rhea-AI Filing Summary

SpyGlass Pharma director Habib J. Dable was granted stock options to acquire 27,400 shares of common stock on February 5, 2026. The options have an exercise price of $16 per share and were awarded as a derivative security grant.

According to the award terms, the options vest over three years, with one thirty-sixth of the shares vesting each month after the grant date, so long as Dable continues to serve as an Outside Director under the company’s 2026 Equity Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dable Habib J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	27,400	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 27,400 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dable Habib J

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		27,400		(1)	02/05/2036	Common Stock	27,400	$0	27,400	D

Explanation of Responses:

1. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SpyGlass Pharma (SGP) report for Habib J. Dable?

SpyGlass Pharma reported a grant of stock options to director Habib J. Dable. He received rights to acquire 27,400 shares of common stock as of February 5, 2026, under the company’s 2026 Equity Incentive Plan.

What are the key terms of Habib J. Dable’s SpyGlass Pharma stock option grant?

The stock option grant allows Habib J. Dable to buy 27,400 SpyGlass Pharma shares at an exercise price of $16. These options were granted on February 5, 2026, as a derivative security award reported on a Form 4 filing.

How do Habib J. Dable’s SpyGlass Pharma options vest over time?

The options vest in 36 equal monthly installments. One thirty-sixth of the 27,400 underlying shares vests each month after the February 5, 2026 grant date, so long as Dable continues serving as an Outside Director under the 2026 Equity Incentive Plan.

What role does Habib J. Dable hold at SpyGlass Pharma (SGP)?

Habib J. Dable is a director of SpyGlass Pharma. His status as an Outside Director under the 2026 Equity Incentive Plan is a condition for continued vesting of the 27,400-share stock option grant reported in this Form 4.

Is Habib J. Dable’s SpyGlass Pharma option grant a purchase or an award?

The transaction is an award, not an open-market purchase. The Form 4 classifies it as a grant or other acquisition of derivative securities, giving Dable the right to buy shares later at a fixed exercise price of $16.